Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Enterprise Value (2020 - 2025)

Bolt Biotherapeutics' Enterprise Value history spans 6 years, with the latest figure at -$31.9 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 214.14% year-over-year to -$31.9 million; the TTM value through Sep 2025 reached -$31.9 million, down 214.14%, while the annual FY2024 figure was -$8.0 million, 92.18% up from the prior year.
  • Enterprise Value for Q3 2025 was -$31.9 million at Bolt Biotherapeutics, down from -$10.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$8.0 million in Q4 2024 and bottomed at -$266.7 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$125.9 million (2023), against an average of -$122.5 million.
  • The largest annual shift saw Enterprise Value crashed 2196.1% in 2021 before it soared 92.18% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$186.2 million in 2021, then grew by 9.31% to -$168.9 million in 2022, then skyrocketed by 39.49% to -$102.2 million in 2023, then skyrocketed by 92.18% to -$8.0 million in 2024, then plummeted by 299.42% to -$31.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Enterprise Value are -$31.9 million (Q3 2025), -$10.4 million (Q2 2025), and -$9.2 million (Q1 2025).